Survey: Half of docs less confident in Boston Scientific after defib hold
April 8, 2010 by MassDevice staff
A survey indicates that Boston Scientific's suspension of its defibrillator operations caused doctors' confidence in the company's products to plunge, with more than half of those polled saying they're less likely to use BSX devices in the future.
A survey of 70 electrophysiologists indicates that the impact of Boston Scientific Corp.'s (NYSE:BSX) suspension of its defibrillator operations last month will have long-lasting consequences for the medical device maker.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
Navigation
NEWS
Can a smartphone help spot a stroke? | MassDevice.com On Call
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help...
Chest docs include Covidien's superDimension lung biopsy device in guidelines
The lung biopsy device acquired by Covidien in its superDimension acquisition is included in new...
Medtronic hits 52-week high on Q4, FY2013 results
Investors sent Medtronic shares to a 52-week high yesterday after the world's largest medical device...
MassDevice.com +3 | The top 3 med-tech stories for May 21, 2013
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Maquet acquires LAAx and its TigerPaw II heart implant
Getinge Group's medical device subsidiary Maquet Cardiovascular buys LAAx and its TigerPaw heart...
